Related Experiment Videos
Reversible Fanconi syndrome associated with valproate therapy
M B Lande1, M S Kim, C Bartlett
1Division of Nephrology, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
The Journal of Pediatrics
|August 1, 1993
Summary
Valproate therapy can cause Fanconi syndrome in children with developmental delay and seizures. Discontinuing the medication led to recovery of kidney function in affected children.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
- Developmental Neurology
Background:
- Valproate is a widely used antiepileptic drug for managing seizure disorders.
- Developmental delay and seizure disorders are complex conditions requiring long-term management.
- Valproate therapy has been associated with various adverse effects, necessitating ongoing safety monitoring.
Observation:
- Two pediatric patients with developmental delay and seizure disorders were treated with valproate.
- These patients subsequently developed Fanconi syndrome, a condition characterized by proximal tubular dysfunction.
- The onset of Fanconi syndrome was temporally linked to valproate administration.
Findings:
- Discontinuation of valproate therapy resulted in the resolution of Fanconi syndrome in both children.
- Normal proximal tubular function was restored within a four-month period after cessation of valproate.
- This suggests a direct causal link between valproate and the development of Fanconi syndrome in this population.
Implications:
- Clinicians should be vigilant for signs of Fanconi syndrome in pediatric patients receiving valproate, especially those with pre-existing developmental or neurological conditions.
- Early recognition and discontinuation of valproate may prevent long-term renal complications.
- Further research is warranted to elucidate the precise mechanisms underlying valproate-induced nephrotoxicity and to identify potential risk factors.